Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase Dosing Schedules for Tumor Lysis Syndrome
NCT00628628Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2008
- Primary completion
- May 2012
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rasburicase in tumor lysis syndrome (TLS), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2008; status: completed.
02
Drugs
rasburicase
03
Conditions
tumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT00628628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00628628.